Incyte (INCY) versus ALGAE TEC LTD/S (ALGXY) Head to Head Analysis

Incyte (NASDAQ:INCY) and ALGAE TEC LTD/S (OTCMKTS:ALGXY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Earnings and Valuation

This table compares Incyte and ALGAE TEC LTD/S’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Incyte $1.54 billion 10.86 -$313.14 million $0.64 122.53
ALGAE TEC LTD/S $2.05 million 1.71 -$6.08 million N/A N/A

ALGAE TEC LTD/S has lower revenue, but higher earnings than Incyte.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Incyte and ALGAE TEC LTD/S, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte 0 8 12 1 2.67
ALGAE TEC LTD/S 0 0 0 0 N/A

Incyte presently has a consensus target price of $88.67, indicating a potential upside of 13.08%. Given Incyte’s higher possible upside, analysts plainly believe Incyte is more favorable than ALGAE TEC LTD/S.

Profitability

This table compares Incyte and ALGAE TEC LTD/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Incyte -6.07% 2.23% 1.59%
ALGAE TEC LTD/S N/A N/A N/A

Volatility & Risk

Incyte has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, ALGAE TEC LTD/S has a beta of 91.26, suggesting that its stock price is 9,026% more volatile than the S&P 500.

Insider & Institutional Ownership

90.6% of Incyte shares are held by institutional investors. Comparatively, 0.1% of ALGAE TEC LTD/S shares are held by institutional investors. 17.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Incyte beats ALGAE TEC LTD/S on 9 of the 12 factors compared between the two stocks.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

About ALGAE TEC LTD/S

Affinity Energy and Health Limited operates as a plant-based health and wellbeing company in Australia, India, and the United States. It engages in developing technology to produce commercial quantities of algae and medicinal cannabis for supply to algae-based nutraceuticals, animal feed and aquaculture, medicinal cannabis, and biofuels markets. The company offers FeedMe Algae, an algae-based aqua feed; and algae-based biofuels. Affinity Energy and Health Limited was founded in 2007 and is based in Subiaco, Australia.

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply